Home  |   Archive  |   Online Submission  |   News & Events  |   Subscribe  |   APFA  |   Society  |   Contact Us  |   中文版
Search   
 
Journal

Ahead of print
Authors' Accepted
    Manuscripts
new!
Current Issue
Archive
Acknowledgments
Special Issues
Browse by Category

Manuscript Submission

Online Submission
Online Review
Instruction for Authors
Instruction for Reviewers
English Corner new!

About AJA

About AJA
Editorial Board
Contact Us
News

Resources & Services

Advertisement
Subscription
Email alert
Proceedings
Reprints

Download area

Copyright licence
EndNote style file
Manuscript word template
Guidance for AJA figures
    preparation (in English)

Guidance for AJA figures
    preparation (in Chinese)

Proof-reading for the
    authors

AJA Club (in English)
AJA Club (in Chinese)

 
Abstract

Volume 15, Issue 3 (May 2013) 15, 362–363; 10.1038/aja.2013.30

Targeting psychoemotional stress to treat prostate cancer

George Kulik

Department of Cancer Biology, Department of Urology, and Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA

Correspondence: Dr G Kulik, (gkulik@wakehealth.edu)

Advance online publication 15 April 2013

Abstract

Earlier epidemiological studies identified diet as a primary environmental factor that determines substantial differences in prostate cancer incidence and mortality between East Asian and West European societies. New data from experiments performed in tissue culture and with animal models as well as epidemiological studies suggest that psychoemotional stress could be a second environmental component that influences prostate cancer progression by activation of epinephrine/beta(2)-adrenergic receptor signaling in the tumor cells. The emerging information on the role of stress in prostate cancer progression provides an additional incentive to actively treat anxiety and depression—frequent psychogenic comorbidities of prostate cancer. Given that almost 50% of men diagnosed with prostate cancer take medications to control hypertension, the choice of beta-blockers for these patients capable of antagonizing both beta(1)-and beta(2)-adrenergic receptors would provide a means of cancer therapy, whereas for men with normal blood pressure, using beta(2)-selective antagonists will help to minimize side effects.

PDF | PDF |

 
Browse:  4454
 
Asian Journal of Andrology CN 31-1795/R ISSN 1008-682X  Copyright © 2023  Shanghai Materia Medica, Chinese Academy of Sciences.  All rights reserved.